Investigation of relationship between the pharmacokinetics of and clinical responses to prochlorperazine in patients receiving opioids

丙氯哌嗪通过抑制多巴胺D2受体而具有高效的止吐作用，常用于治疗癌症患者阿片类药物引起的恶心和呕吐。接受阿片类药物治疗的患者对丙氯哌嗪的临床反应各不相同。阿片类药物与下丘脑上的阿片受体MU1结合，从而导致多巴胺能通路的阻断。这项研究基于接受阿片类药物治疗的患者的非遗传和遗传因素，评估了丙氯丙嗪的药代动力学和临床反应的个体间差异。

Prochlorperazine has a high potency antiemetic effect based on inhibiting dopamine D2 receptor and is commonly used for the treatment of opioid-induced nausea and vomiting in cancer patients. Clinical responses to prochlorperazine vary in patients receiving opioids. Opioids bind to opioid receptor mu1 on the hypothalamus and subsequently cause the blockade of dopaminergic pathways. This study evaluated the interindividual variation in pharmacokinetics of and clinical responses to prochlorperazine based on non-genetic and genetic factors in patients receiving opioids.